Pentoxifylline Studied for Diabetic Kidney Disease
A new clinical trial evaluates if an established drug can help improve kidney health outcomes in adults with diabetes.
Updated on Oct. 29, 2026 in Diabetes
Live Poll
Should medical research prioritize testing older, inexpensive drugs against newer, costlier medical treatments?
Researchers recently presented baseline data from a large-scale study evaluating the use of the older drug pentoxifylline in treating diabetic kidney disease. The trial, which focuses on patients currently managed with modern standard-of-care medications, aims to determine if the drug can effectively prevent disease progression.
Why it matters
While standard treatments exist, many patients with diabetic kidney disease continue to experience poor outcomes, prompting research into whether repurposed, cost-effective medications could provide additional clinical benefits.
This ongoing randomized controlled trial includes 2,376 veterans, with 50% of participants currently taking SGLT2 inhibitors at baseline. Because findings are based on baseline characteristics and the trial is ongoing, evidence on treatment efficacy remains preliminary.
The players
Veterans Affairs
A federal department responsible for providing comprehensive healthcare services to military veterans, including specialized programs for chronic conditions like diabetes.
ASN Kidney Week
An annual professional gathering organized by the American Society of Nephrology where researchers share the latest clinical and basic science findings in kidney health.
The details
Pentoxifylline is a medication originally approved by the FDA in 1984 for peripheral vascular disease that researchers are now testing for kidney protection. In this study, participants are randomized to receive either a placebo or 400 mg of the drug, with the dosage increasing to twice daily after five weeks. The primary goal is to assess the medication's impact on the time to either all-cause death or the development of end-stage kidney disease.
Timeline
The FDA initially approved pentoxifylline for peripheral vascular disease in 1984.
The study concept originated in 2015.
Baseline data were presented at ASN Kidney Week on October 21-25, 2026.
Health Landscape
This study addresses the critical need for affordable, accessible treatment options in the evolving standard of care for diabetic kidney disease. It sits within a broader research trend of re-evaluating legacy medications alongside modern therapies like SGLT2 inhibitors to improve long-term outcomes.
This study is an ongoing research project and does not currently change clinical practice or treatment guidelines. Patients interested in how new research applies to their specific management plan should have a conversation with their physician.
The takeaway
Ongoing research into repurposed drugs aims to provide more options for managing diabetic kidney disease. Patients should maintain their current treatment regimen and discuss any questions about emerging clinical trials with their primary healthcare provider.
Further reading
For more on managing long-term kidney health, explore our Diabetes section.
More information
Review the full clinical trial study details on the official registry.
Source note: This article includes information reported by Hcplive.
Live Poll
Should medical research prioritize testing older, inexpensive drugs against newer, costlier medical treatments?
